These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study. Saviano S; Leon PE; Mangogna A; Tognetto D Digit J Ophthalmol; 2016; 22(2):46-53. PubMed ID: 27582675 [TBL] [Abstract][Full Text] [Related]
6. One-year outcomes of less frequent bevacizumab in age-related macular degeneration. Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363 [TBL] [Abstract][Full Text] [Related]
7. Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia. Karasu B; Gunay BO Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):99-106. PubMed ID: 31768680 [TBL] [Abstract][Full Text] [Related]
8. Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation. Hufendiek K; Hufendiek K; Panagakis G; Helbig H; Gamulescu MA Int Ophthalmol; 2012 Jun; 32(3):259-68. PubMed ID: 22527448 [TBL] [Abstract][Full Text] [Related]
9. Short-term effects of a single intravitreal bevacizumab injection on retinal vessel calibre. Tatlipinar S; Dinç UA; Yenerel NM; Görgün E Clin Exp Optom; 2012 Jan; 95(1):94-8. PubMed ID: 21954975 [TBL] [Abstract][Full Text] [Related]
10. Predicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision. Frenkel RE; Shapiro H; Stoilov I Br J Ophthalmol; 2016 Aug; 100(8):1052-7. PubMed ID: 26541435 [TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A Retina; 2007; 27(4):432-8. PubMed ID: 17420694 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy. Rush RB; Rush SW; Aragon AV; Ysasaga JE Am J Ophthalmol; 2014 Aug; 158(2):337-44. PubMed ID: 24844972 [TBL] [Abstract][Full Text] [Related]
13. Baseline Predictors for Good Versus Poor Visual Outcomes in the Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Therapy. Chae B; Jung JJ; Mrejen S; Gallego-Pinazo R; Yannuzzi NA; Patel SN; Chen CY; Marsiglia M; Boddu S; Freund KB Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5040-7. PubMed ID: 26237196 [TBL] [Abstract][Full Text] [Related]
14. INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: 5-Year Results of The Pan-American Collaborative Retina Study Group. Arevalo JF; Lasave AF; Wu L; Acón D; Berrocal MH; Diaz-Llopis M; Gallego-Pinazo R; Serrano MA; Alezzandrini AA; Rojas S; Maia M; Lujan S; Retina; 2016 May; 36(5):859-67. PubMed ID: 26529555 [TBL] [Abstract][Full Text] [Related]
15. [Intravitreal bevacizumab in AMD complicated by submacular hemorrhage]. Bouraoui R; Bouladi M; Kort F; Limaiem R; Mghaieth F; El Matri L J Fr Ophtalmol; 2016 Mar; 39(3):248-54. PubMed ID: 26995076 [TBL] [Abstract][Full Text] [Related]
16. Intravitreal Bevacizumab Versus Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration: Findings from a Cochrane Systematic Review. Solomon SD; Lindsley KB; Krzystolik MG; Vedula SS; Hawkins BS Ophthalmology; 2016 Jan; 123(1):70-77.e1. PubMed ID: 26477843 [TBL] [Abstract][Full Text] [Related]
17. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration]. Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687 [TBL] [Abstract][Full Text] [Related]
18. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics. Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560 [TBL] [Abstract][Full Text] [Related]
19. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Lazic R; Gabric N Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776 [TBL] [Abstract][Full Text] [Related]